New lung disease treatment opens for early access
NCT ID NCT05344508
Summary
This program provides early access to brensocatib for adults with non-cystic fibrosis bronchiectasis who completed a previous clinical trial. Participants take a daily tablet to help control their chronic lung condition. The goal is to continue managing the disease while the treatment undergoes regulatory review.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.